AbbVie presents applications to FDA and EMA for approval of SKYRIZI in psoriatic arthritis

AbbVie presents applications to FDA and EMA for approval of SKYRIZI in psoriatic arthritis

Source: 
Pharmaceutical Business Review
snippet: 

AbbVie has submitted applications seeking approval for SKYRIZI (risankizumab-rzaa, 150 mg) and SKYRIZI (risankizumab, 150 mg) to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), respectively, for the treatment of adults with active psoriatic arthritis.